LGD 4033 - Dragon Pharma

Ligandrol (LGD-4033) is a potent selective androgen receptor modulator (SARM) developed by Ligand Pharmaceuticals in 2007 and later licensed to Viking Pharmaceuticals. It targets androgen receptors in muscle and bone, promoting muscle growth and bone density without significant androgenic effects in other tissues. Clinical trials have shown substantial increases in lean body mass without notable fat gain. However, Ligandrol is known for suppressing natural testosterone production and negatively impacting HDL cholesterol, requiring careful post-cycle management to mitigate these effects .

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about LGD 4033 by Dragon Pharma, consult with your doctor or healthcare professional.